We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gemcitabine With Curcumin for Pancreatic Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00192842
First Posted: September 19, 2005
Last Update Posted: September 22, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rambam Health Care Campus
September 12, 2005
September 19, 2005
September 22, 2010
July 2004
November 2007   (Final data collection date for primary outcome measure)
time to tumor progression
Same as current
Complete list of historical versions of study NCT00192842 on ClinicalTrials.gov Archive Site
  • response rate
  • survival
  • clinical benefit
  • toxicity
Same as current
Not Provided
Not Provided
 
Gemcitabine With Curcumin for Pancreatic Cancer
Phase II Trial of Gemcitabine and Curcumin in Patients With Advanced Pancreatic Cancer
The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Pancreatic Cancer
Drug: curcumin (+ gemcitabine)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
17
September 2010
November 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • locally advanced or metastatic adenocarcinoma of the pancreas
  • no prior chemotherapy
  • performance status 0-2
  • adequate hematology and chemistry

Exclusion Criteria:

  • serious concurrent medical condition
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Israel
 
NCT00192842
RonCurcuminPancreas.CTIL
No
Not Provided
Not Provided
Not Provided
Rambam Health Care Campus
Not Provided
Principal Investigator: Ron Epelbaum, MD
Rambam Health Care Campus
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP